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Our purpose was to determine the efficacy of irinotecan plus paclitaxel administered on day 1, repeated every 2 weeks, in untreated
patients with advanced or metastatic non-small-cell lung cancer (NSCLC). In total, 56 patients with inoperable or metastatic stage III
and IV NSCLC with a histologically or cytologically confirmed diagnosis were enrolled. None of the patients had undergone prior
chemotherapy or radiation therapy. Treatment involved irinotecan 125mgm
 2 and paclitaxel 135mgm
 2 administered on day 1
and repeated every 2 weeks for a planned number of nine cycles. With a standard dose of paclitaxel at 135mgm
 2, the dosage of
irinotecan was escalated at four levels: 75, 100, 125 and 150mgm
 2; 125mgm
 2 was established as the maximum tolerated dose;
this dosage was administered to 46 patients. A total of 52 patients (median age 65 years, range 38–77 years) were assessable for
toxicity and survival and 46 for response rate. Out of 46 evaluable patients, 19 achieved partial response (41.3%), 17 had stable
disease (37%) and 10 (21.7%) experienced disease progression. The median duration of response was 6 months (range 2–9þ
months). The main adverse reactions were myelotoxicity (grades 3 and 4) in 10 (19.2%) patients and diarrhoea (grade 3) in four
(7.7%) patients. Irinotecan combined with paclitaxel, administered every 2 weeks, appears to be an effective treatment for advanced-
stage NSCLC.
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Advanced-stage non-small-cell lung cancer (NSCLC) patients are
still in need of new chemotherapy agents that will improve
response rate and survival. New agents have been effectively
established for other malignant tumours but very few have been
applied in cases of NSCLC. One class of recent cytotoxic drugs are
the camptothecins. Irinotecan (CPT-11) is a semisynthetic
derivative of camptothecin, which produces a cytotoxic effect
through interaction with and stabilisation of DNA/topoisomerase-I
cleavable complexes by the active metabolite SN-38. The collision
of the transcription apparatus and the stabilisation of the cleavable
complex cause damage and lead to cell death (Douillard et al, 2000;
Sargent et al, 2001). Irinotecan has been administered in colorectal
cancer, mainly in combination with other agents in advanced
disease (Wasserman et al, 1999; Saltz et al, 2000; Goldberg et al,
2004); it is also effective in pancreatic cancer (Rocha-Lima et al,
2002; Stathopoulos et al, 2003). The choice of irinotecan for
gastrointestinal cancers is more or less empirical and use within
clinical trials for other malignant tumours may show equal
effectiveness. Existing data combining irinotecan with other agents
such as cisplatin (Cardenal et al, 2003) show an effectiveness
comparable to other established treatments in NSCLC (Negoro
et al, 2003). For the present study, the second agent selected for
combination treatment with irinotecan was paclitaxel, which has
been tested as first-line combined treatment for advanced NSCLC
(Chang et al, 1996; Greco and Hainsworth, 1997; Belani et al, 1999;
Bonomi et al, 2000; Stathopoulos et al, 2004). In vitro combination
studies of topoisomerase inhibitors with taxanes have shown
conflicting results. In one preclinical study, the combination of a
topoisomerase inhibitor in combination with paclitaxel demon-
strated synergistic cytotoxicity (Chou et al, 1994). Another
preclinical study has shown that this combination in human
NSCLC cell lines is antagonistic (Kaufmann et al, 1996). One
interpretation is that these interactions may vary, depending on
the cell type studied and the sequence of drug administration
(Adjei et al, 2000). It was suggested that this combination be tested
in clinical trials.
In the present phase I–II trial, we combined paclitaxel with
irinotecan, administering both agents on the same day, repeating
treatment every 2 weeks. This biweekly (every 2 weeks)
chemotherapy schedule was based on recent trials with proper
dosage adjustment and a successful outcome (Cardenal et al, 2003;
Negoro et al, 2003). Our objectives were to determine response
rate, toxicity, and median and overall survival.
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sPATIENTS AND METHODS
Eligibility criteria
Eligibility for the study required the following: histologically or
cytologically confirmed NSCLC, disease staging (operation for
staging was permitted) and defined inoperable stage IIIB, IV, no
prior chemotherapy or radiotherapy, bidimensionally measurable
disease on physical examination, X-rays, computed tomography
(CT), World Health Organisation (WHO) performance status 0–2,
expected survival X12 weeks, adequate bone marrow reserve
(leucocyte count X3500ml
 1, platelet count X100000ml
 1 and
haemoglobin X10gdl
 1), adequate renal function (serum creati-
nine p1.5mgdl
 1) and liver function (serum bilirubin
p1.5mgdl
 1 and serum transaminases p three times the upper
limit of normal (or p five times the upper limit of normal in cases
of liver metastases]), and age X18 years. In cases with central
nervous system (CNS) involvement or any secondary malignancy,
patients were excluded. This study was conducted with the
approval of our institutional review board and all patients gave
their informed consent before entering the study.
Treatment plan
Paclitaxel and irinotecan were administered in different intensities:
once weekly or every 3 weeks with adjusted doses. Paclitaxel was
given biweekly (once every 2 weeks) at a dose of 135mgm
 2,i n
combination with a second agent, and toxicity was well-tolerated
(Stathopoulos et al, 2004). The dose of irinotecan combined with
another agent, administered on days 1 and 8, repeated every 21
days, varied from 60 to 110mgm
 2 (Kakolyris et al, 2000, 2001;
Keresztes et al, 2004). In the present study, our intention was to
conduct a phase I study by escalating the dosage of irinotecan
while keeping paclitaxel at a standard dose. This was considered
necessary since the dose of irinotecan had not been established
when given once every 2 weeks in combination with another
myelotoxic agent. On the basis of the previously mentioned data,
we determined the dosages as follows: four levels of irinotecan
starting at 75mgm
 2, increasing the dose by 25mgm
 2 and
ending at a dose of 150mgm
 2. We intended to increase the latter
to a higher dose if it was well tolerated. The dose of paclitaxel
remained at 135mgm
 2, as this had been tested in a biweekly
administration in combination with other myelotoxic agents such
as carboplatin or navelbine (Stathopoulos et al, 2004). Table 1
shows dose escalation. When the maximum tolerated dose (MTD)
was decided upon (detected or reached), it was given to the next
recruited patients. Both drugs were infused: first, irinotecan in
normal saline 500cm
3 for 90min and then paclitaxel in a solution
of 300mol mixture of 5% dextrose and normal saline for a 3-h
infusion. Premedication of 8mg dexamethasone and 50mg
diphenhydramine was given 1h before paclitaxel administration
and repeated every 8h for the first day and once daily on days 2
and 3. Ranitidine in a normal saline infusion was given at the
beginning of the treatment. Ondansetron (8mg) was also
administered at the beginning and at the end of the infusions.
The treatment plan was to repeat the drug administration every 2
weeks for nine cycles unless there was disease progression. In cases
of myelotoxicity (neutropenia or thrombocytopenia), dose adjust-
ments within a cycle were based on weekly absolute granulocyte
and platelet counts and clinical assessment.
Baseline and treatment assessments and evaluation
Before study entry, all patients underwent the following evalua-
tions: physical examination, tumour evaluation or measurement,
WHO performance status, ECG, full blood count, liver and kidney
function tests and urinalysis. Staging was determined by chest and
abdominal CT scans, bone scan and occasional magnetic
resonance imaging. Blood count, blood urea and serum creatinine
were measured before each treatment administration and 7 days
after treatment. During the treatment period, radiologic tests were
conducted after four courses, at the end of the study and after any
course if the clinical signs were indicative of disease progression.
Response and toxicity were assessed using standard WHO
criteria. Complete response (CR) was considered to be the
complete disappearance of any sign of demonstrable disease,
partial response (PR) as X50% reduction of measurable disease
and stable disease (SD) as a o50% reduction or a o25% increase
in the sum of the products of the two perpendicular diameters of
all measured lesions and the appearance of no new lesions for 8
weeks. Progressive disease (PD) was defined as an increase in the
product of the two perpendicular diameters of any measurable
lesion by 25% over the size at the time of maximum regression and
the appearance of new areas of malignant disease. The duration of
response was measured from the documentation of response (CR
or PR) to PD. The time to tumour progression (TTP) was
measured from the time of the first dose administration to disease
progression. The determination of objective response on com-
puted tomography was performed by two independent radiologists
and two experienced oncologists.
Statistical design
This was an expected two-step phase II study after the integration
of the phase I study. According to the trial design, 30 patients were
to be enrolled during the first part of the study, and if an objective
response rate of o15% was achieved, the treatment would have
been abandoned; otherwise, 20 additional patients were to be
enrolled. The primary end point of the study was the efficacy of the
regimen and the secondary end points were overall survival (OS)
and tolerance. Overall survival was calculated from the day of
enrolment until death. The median probability of survival and
median TTP were estimated by the Kaplan–Meier method;
confidence intervals (CIs) for response rates were calculated using
methods for the exact binomial CI.
RESULTS
Of the 56 intent-to-treat patients with advanced inoperable NSCLC,
enrolled in the study between October 2003 and February 2005, 52
(92.9%) were evaluable for toxicity and survival. A total of 46
patients were evaluated for response rate. Three patients at dose
escalation level 1 and three at level 2 were excluded as the dosage
they received was inferior to the MTD. Four out of 56 patients were
nonevaluable: two refused to continue after the first infusion and
the other two were excluded due to cardiac disease nonrelated to
the toxicity of the treatment. A total of 47 (83.9%) patients were
male and nine (16.1%) were female (median age 65 years, range
38–77 years), and 25 and 31 were stage IIIB and IV, respectively.
The patients’ characteristics at baseline are shown in Table 2.
Histology showed 21 squamous cell type, 19 adenocarcinoma, one
Table 1 Dose escalation scheme
Dose level
Irinotecan
(mgm
 2)
Paclitaxel
(mgm
 2)
No. of
patients Courses
1 75 135 3 12
2 100 135 3 12
3 125 135 3+43
a 282
4 150 135 6 12
Total 318
aA total of 43 patients were in the phase II part of the study, at this dose level.
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slarge cell type and 15 undifferentiated or nondefined by cytological
examination.
Compliance with treatment–dose intensity
In total, 318 chemotherapy cycles were administered with a median
of 6.63 cycles (range 2–9) per patient. The median interval
between cycles was 15 days (range 15–22 days). Expected dose
intensity for paclitaxel was 67.5mgm
 2 week
 1 (mean dose
intensity 66.2mgm
 2week
 1); the 95% CI was 65.1–
67.2mgm
 2week
 1 (median dose intensity 67.5mgm
 2week
 1,
range 54–67.5mgm
 2week
 1). The expected dose intensity
for irinotecan was 60mgm
 2week
 1 (mean dose intensity
59mgm
 2week
 1); the 95% CI was 58.3–59.8mgm
 2week
 1
(median 60mgm
 2week
 1, range 50–60mgm
 2week
 1). In four
patients, four cycles (once per patient) were delayed by 1 week.
Three out of six patients at level four presented with grade 4
neutropenia and four out of six had grade 2 or 3 diarrhoea. In
patients at dosage levels 1 and 2, grade 1 neutropenia and grade 1
or 2 diarrhoea were observed in two out of six patients. Of the 46
patients included in the phase II study (at dosage level 3), in two
the dosage of both cytotoxic agents was reduced by 25% (after the
third cycle in one, and after the fourth in the other). Treatment
delay or dose reduction was due to grade 3 or 4 neutropenia in five
cases and to hepatotoxicity (transaminasemia reversible) in one
case. At the time of this analysis, 25 patients were still alive (48.1%)
with a median follow-up time of 10 months (range 5–16 months).
The Kaplan–Meier method was used for survival distribution
estimation (Figure 1).
Response rate and survival
An objective response rate was observed in 19 out of the 46
evaluable patients (41.3%), with a median duration of response of
6 months (range 2–9þ). The response rate and duration by stage
are shown in Table 3. The responders were PR and there were no
CRs. A total of 17 patients showed SD (37%) and 10 patients had
disease progression (21.7%). The median TTP was 6 months
(range 2–11þ months).
Toxicity
In the 15 patients included in the phase I escalation testing, no
serious toxicity was observed at levels 1 and 2. Haematologic
toxicity was, in general, acceptable at the level 3 dose (125mgm
 2
of irinotecan and 135mgm
 2 of paclitaxel). With regard to the
level 4 dosage, 50% of the patients presented with grade 4
neutropenia and grade 3 diarrhoea. Serious neutropenia was
observed in 10 patients (19.2%): eight with grade 3 (15.4%) and
two with grade 4 (3.8%). Febrile neutropenia was seen in three
(5.8%) of these patients. All of the above patients were treated with
haemopoietic growth factor, given on days 6–8 following the
previous treatment cycle. Anaemia was common (23 patients), but
only four had grade 3 (7.7%). Grades 1 and 2 thrombocytopenia
were uncommon (five patients, 9.6%) (Table 4). Mild nonhaema-
tologic toxicity was observed in the majority of the cases: grade 3
toxicity with diarrhoea in four patients (7.7%), alopecia in four
patients (7.7%), fatigue in one patient (1.9%) and allergy in one
patient (1.9%). Nonhaematologic toxicity is shown in Table 5.
DISCUSSION
This trial was planned in order to test a new combination as first-
line treatment in advanced and inoperable NSCLC. Paclitaxel, one
of the two agents, is an established drug in a combined modality
for NSCLC patients. Much data exist where paclitaxel has been
administered with different agents (mainly cisplatin or carbopla-
tin) (Akerley et al, 1997; Belani et al, 1999; Frasci et al, 1999;
Bonomi et al, 2000; Johnson et al, 2004) as first-line treatment in
advanced NSCLC. Irinotecan has been administered in NSCLC
with agents other than paclitaxel either as second-line (Kakolyris
Table 2 Patients’ characteristics at baseline
Characteristic No. of patients %
No. of patients enrolled 56
No. of patients assessable 52 92.9
Age (years)
Median, 65
Range, 38–77
Gender
Male 47 83.9
Female 9 16.1
Performance status (WHO)
0 12 21.4
1 33 58.9
2 11 19.6
Stage of disease
IIIB 25 44.6
IV 31 55.4
Total 56 100
Histologic type
Squamous 21 37.5
Adenocarcinoma 19 33.9
Large cell 1 1.8
Undifferentiated 15 26.8
Total 56 100
Tumour differentiation
Well differentiated 2 3.6
Moderately differentiated 18 32.1
Poorly differentiated 36 64.3
Metastatic site
Bone 13 41.9
Liver 10 32.3
Lung 4 12.9
Adrenal 2 6.5
Brain 1 3.2
Pancreas 1 3.2
Total 31
0.0
0.2
0.4
0.6
0.8
1.0
C
u
m
u
l
a
t
i
v
e
 
p
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
 
0 2 4 6 8 1 01 21 41 61 82 0
Survival time (months)
Survival function (Kalpan–Meier method)
Figure 1 Survival distribution estimation (Kaplan–Meier method).
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set al, 2000, 2001; Keresztes et al, 2004; Ohyanagi et al, 2004) or as
front-line treatment with cisplatin (Cardenal et al, 2003; Negoro
et al, 2003). It was our hope to further determine the cytotoxic
value and effectiveness of irinotecan in NSCLC. In recent years,
several new agents have been introduced for the treatment of
advanced NSCLC. Some have an established effectiveness, such as
taxanes, including docetaxel (Fossella et al, 2000; Georgoulias et al,
2001), gemcitabine (Crino et al, 1997, 1999) and vinorelbine (Le
Chevalier et al, 1994; Kouroussis et al, 1998), as well as paclitaxel.
Although other new tested agents exist, their effectiveness needs to
be confirmed: teniposide, premetrexed and irinotecan are already
in use in NSCLC clinical trials. Teniposide in combination with
cisplatin produced a reasonably high response rate (41%) with a
1-year survival of 43% (Giaccone et al, 1998). Premetrexed was
initially tested as second-line treatment and produced a 23.3%
response rate, with quite high but acceptable toxicity (Rusthoven
et al, 1999). Then, premetrexed was combined with cisplatin as
first-line treatment and the combination was effective with a 45.8%
response rate, 8.5 months median survival and 40% 1-year survival
(Shepherd et al, 2001). Irinotecan may prove to be a promising
agent but further confirmatory trials are required. The existing
data are mainly related to second-line treatment using irinotecan
on days 1 and 8 and cisplatin on day 8 repeated every 21 days with
doses of 100–110 and 80mgm
 2, respectively: PR was 16.7% and
the main toxicity was grade 3–4 neutropenia (18%) and diarrhoea
(29%) (Kakolyris et al, 2000). Another trial with the same agents
and dosages produced similar toxicity and a 20% response rate,
which cannot be ignored as a second-line chemotherapy following
a docetaxel-based front-line regimen (Kakolyris et al, 2001). In
another randomised study, irinotecan was combined with
docetaxel vs irinotecan with gemcitabine, also as second-line
treatment with or without celecoxib, in patients with NSCLC. The
dose of irinotecan was 60mgm
 2 when combined with docetaxel
and 100mgm
 2 when combined with gemcitabine, administered
on days 1 and 8, with both agents repeated every 21 days. The
response rate was low with a PR of 4–8.5%; toxicity was mainly
diarrhoea in 13–28% of the patients, neutropenia in 20–26%
and thrombocytopenia in up to 34% (the latter was observed only
in the irinotecan–gemcitabine combination) (Keresztes et al,
2004). The combination of irinotecan with gemcitabine was the
object of another trial as second-line treatment for refractory
or relapsed NSCLC. In this latter study, there was a difference, in
comparison to the other aforementioned studies, with respect
to the dosage of irinotecan and to treatment intensity: irinotecan
150mgm
 2 and gemcitabine 1000mgm
 2 were given on days 1
and 15, repeated on day 28. Haematologic toxicity and diarrhoea
were lower at 7.4–14.8 and 3.7%, respectively. The lower toxicity
might have been due to eliminating treatment on the 8th day.
Response was 18.5% (Ohyanagi et al, 2004). All of the above trials
were preliminary with a small number of patients. In our study,
where the drug administration was also every 2 weeks, the
150mgm
 2 dose during phase I, dosage level 4 (six patients),
toxicity related to grade 4 neutropenia was detected in three
out of six (50%) patients and grade 3 diarrhoea in three out of
six (50%) patients. The difference from the previous trial might be
due to the combined second agent, which in our study was
paclitaxel.
Two other trials have tested irinotecan as first-line chemo-
therapy. One study combined irinotecan with cisplatin and both
agents were given on day 1 and repeated every 3 weeks. The dosage
of irinotecan was 200mgm
 2 and cisplatin 80mgm
 2. These
investigators achieved a 34.2% PR rate and the toxicity, again,
was mainly diarrhoea (29%) and febrile neutropenia (14%); the
1-year survival was 31%, and the median survival was 8.2 months
(Cardenal et al, 2003). The other trial with the irinotecan and
cisplatin combination as first-line treatment was a randomised
phase III study, comparing this regimen with the cisplatin and
vindesine combination, and there was also a third arm with
irinotecan alone. The authors concluded that there was no
statistically significant difference among the three arms with
respect to response rate and survival. In the irinotecan–cisplatin
arm, the response rate was higher (50%) than that of the other
arms, but the toxicity was also the highest (diarrhoea 12–15%).
Irinotecan administration was on days 1, 8 and 15, every 4 weeks at
a dose of 60mgm
 2 (Negoro et al, 2003).
In a phase I trial, CPT-11 (irinotecan) was one of the three
agents used in combination with carboplatin and paclitaxel in
NSCLC patients with advanced disease. The treatment was
administered once every 3 weeks. Toxicity was high with 50%
myelotoxicity and 19% febrile neutropenia. These authors suggest
the MTD as CPT-11 100mgm
 2, carboplatin 5 AUC and paclitaxel
175mgm
 2. The response rate of 39% is not higher than that of
other treatments with two agents, but it is quite toxic. The median
survival of 11 months was satisfactory, but it is inconclusive as to
whether or not the addition of CPT-11 to a well-tested two-drug
combination (carboplatin–paclitaxel) affected the efficacy; it is,
however, more or less certain that it increased the toxicity
(Socinski et al, 2001).
The same combination of CPT-11 100mgm
 2, carboplatin 5
AUC and paclitaxel 175mgm
 2 once every 3 weeks was given in a
phase II study by the same group of investigators who consider
that this regimen can be safely administered in NSCLC patients.
There was, however, 78% neutropenia. Responsiveness was 32%
and SD 55%. The median survival was quite remarkable at 12.5
months (Socinski et al, 2002).
Table 3 Response rate and duration
a by stage
PR SD PD Total
Disease stage n (%) n (%) n (%) n (%)
IIIB 11 (23.9) 9 (19.6) 5 (10.9) 25 (54.3)
IV 8 (17.4) 8 (17.4) 5 (10.9) 21 (42.6)
Total 19 (41.3) 17 (37.0) 10 (21.7) 46 (100)
aDuration of response: median 6 months (range 2–9+ months). PR¼partial
response; SD¼stable disease; CR¼complete response.
Table 4 Haematological toxicity
Grade 1 Grade 2 Grade 3 Grade 4
n (%) n (%) n (%) n (%)
Neutropenia
a 3 (5.8) 13 (25) 8 (15.4) 2 (3.8)
Anaemia 17 (32.7) 2 (3.8) 4 (7.7) —
Thrombocytopenia 2 (3.8) 3 (5.8) — —
aFebrile neutropenia in three patients.
Table 5 Nonhaematologic toxicity
Grade 1 Grade 2 Grade 3
n (%) n (%) n (%)
Nausea/vomiting 7 (13.5) — —
Diarrhoea 12 (23.1) 4 (7.7) 4 (7.7)
Alopecia 17 (32.7) 6 (11.5) 4 (7.7)
Fatigue 8 (15.4) — 1 (1.9)
Allergy 5 (9.6) 1 (1.9) 1 (1.9)
Neurotoxicity 4 (7.7) 1 (1.9) —
Myalgia 6 (11.5) — —
Mucositis 5 (9.6) — —
Cardiotoxicity 2 (3.8) — —
Nephrotoxicity 1 (1.9) — —
Hepatotoxicity — — 1 (1.9)
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sAnother phase I study in NSCLC patients, by a Japanese group
of researchers, combined paclitaxel (day 1) with CPT-11 (days 1, 8
and 15) in a 4-week cycle; a dosage of paclitaxel 210mgm
 2 and
CPT-11 50mgm
 2 was defined as dose-limiting toxicity (DLT).
The MTD was 50mgm
 2 for CPT-11 and 180mgm
 2 for
paclitaxel. The repetition of CPT-11 on days 8 and 15 may not
have added to the efficacy but only increased the toxicity (Kasai
et al, 2002).
Similar results are given in another phase I–II study where
paclitaxel and CPT-11 were combined in NSCLC patients.
The treatment was performed every 2 weeks, as in our study,
and the recommended dose was 160mgm
 2 for paclitaxel and
60mgm
 2 for CPT-11 – a higher dose of paclitaxel and a much
lower dose of CPT-11 as compared to ours. Although the number
of patients was only 24, it is interesting to note that the response
rate was 58.3% and the 1-year survival was 54.2% (Yamada
et al, 2004).
A phase I study with the paclitaxel and irinotecan combination
was different from ours and the aforementioned trials, in that the
agents were administered on days 1 and 8 and repeated every 3
weeks. These authors concentrated on the pharmacokinetic
analysis and suggested that the MTD was 40mgm
 2 for irinotecan
and 50mgm
 2 for paclitaxel. Only nine patients were tested and
the effectiveness described was SD (Hotta et al, 2004).
Based on the above, concerning the use of irinotecan in NSCLC,
one can assume that (a) this agent is an effective product for this
disease, particularly when combined with another cytotoxic drug,
and (b) it is nonconclusive as to whether the treatment schedule
should be weekly, biweekly (every 2 weeks) or every 3 weeks. Our
study produced a response rate of 41.3%, which is higher than that
reported in most of the studies with irinotecan and is comparable
to other studies with established chemotherapy schedules. Serious
neutropenia and diarrhoea in the present trial were approximately
20%. Comparing the toxicity in irinotecan trials, it appears that it
is lower and more acceptable when the schedule is repeated every 2
weeks, as shown in our study and also in the other aforementioned
study using a biweekly schedule (Ohyanagi et al, 2004). It appears
that in eliminating the 8th-day repetition of drug administration,
the response rate is not reduced. Whether the biweekly dose of
irinotecan should be 125mgm
 2 as in our trial or 150mgm
 2 as in
the other trial (Ohyanagi et al, 2004) is debatable, since toxicity
and response in both trials were similar. Our lower dose of
irinotecan was decided upon because it was combined with
paclitaxel, a more myelotoxic agent than cisplatin, which was the
agent used in the other study.
Irinotecan combined with paclitaxel as front-line chemotherapy
in advanced or metastatic NSCLC is an effective treatment which,
when given every 2 weeks, produces well-tolerated toxicity.
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